GlassScriptPhysician profile
Louelyn Sazon
NPI 1285450007
$554.29
in general payments reported to CMS, 2019-2025
15 companies · $554 in 2025
The $554 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $554.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Soleno Therapeutics, INC. | $66.81 | 2025 | Vykat Xr |
| Biomarin Pharmaceutical INC. | $62.86 | 2025 | Voxzogo 1.2mg, Palynziq |
| Ns Pharma, INC. | $57.18 | 2025 | Viltepso |
| Amicus Therapeutics, INC. | $51.39 | 2025 | Galafold |
| Alexion Pharmaceuticals, INC. | $49.06 | 2025 | Koselugo |
| Acadia Pharmaceuticals INC | $45.92 | 2025 | Daybue |
| Takeda Pharmaceuticals U.S.A., INC. | $32.82 | 2025 | Vpriv |
| Ptc Therapeutics, INC. | $30.58 | 2025 | |
| Neurelis, INC. | $25.63 | 2025 | Valtoco |
| Eton Pharmaceuticals, INC. | $24.53 | 2025 | Galzin, Carglumic Acid, Nitisinone |
| Mirum Pharmaceuticals, INC. | $22.24 | 2025 | Cholbam |
| Jazz Pharmaceuticals INC. | $22.22 | 2025 | |
| Cycle Pharmaceuticals INC | $21.12 | 2025 | Javygtor |
| Genzyme Corporation | $20.99 | 2025 | |
| Sentynl Therapeutics, INC. | $20.94 | 2025 | Nulibry |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louelyn Sazon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.